ACHL vs. MOLN, VIGL, LIFE, SGMO, DBVT, OMGA, BLUE, CGTX, ATHA, and IGNY
Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Molecular Partners (MOLN), Vigil Neuroscience (VIGL), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), DBV Technologies (DBVT), Omega Therapeutics (OMGA), bluebird bio (BLUE), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), and Ignyte Acquisition (IGNY). These companies are all part of the "biological products, except diagnostic" industry.
Molecular Partners (NASDAQ:MOLN) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
In the previous week, Achilles Therapeutics had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Achilles Therapeutics and 2 mentions for Molecular Partners. Achilles Therapeutics' average media sentiment score of 1.88 beat Molecular Partners' score of 1.26 indicating that Molecular Partners is being referred to more favorably in the media.
Achilles Therapeutics received 6 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 54.84% of users gave Achilles Therapeutics an outperform vote while only 44.00% of users gave Molecular Partners an outperform vote.
Molecular Partners has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Molecular Partners has higher revenue and earnings than Achilles Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Achilles Therapeutics has a net margin of 0.00% compared to Achilles Therapeutics' net margin of -864.73%. Achilles Therapeutics' return on equity of -31.42% beat Molecular Partners' return on equity.
Molecular Partners currently has a consensus price target of $4.50, indicating a potential upside of 18.42%. Achilles Therapeutics has a consensus price target of $4.00, indicating a potential upside of 339.56%. Given Molecular Partners' higher possible upside, analysts clearly believe Achilles Therapeutics is more favorable than Molecular Partners.
26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by company insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Achilles Therapeutics beats Molecular Partners on 10 of the 16 factors compared between the two stocks.
Get Achilles Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achilles Therapeutics Competitors List
Related Companies and Tools
